Skip to main content
PATIENT IDENTIFICATION

Are your patients like Jamie-Lynn ready for something different?

_

Actual patient taking KESIMPTA who was compensated for time. Individual results may vary.

For relapsing MS patients, disease activity can mean disability progression1

More frequent relapses, MRI activity, and new or worsening symptoms are all signs of active relapsing MS.1,2

*Results from the MS in America Study, an online survey conducted in 2013 and completed by 2562 adult MS patients who were US residents or citizens living abroad.3
Analysis of US Symphony Anonymous Patient Level Data from November 2019-October 2020 pertaining to patients with MS. High efficacy therapies include ocrelizumab, natalizumab, alemtuzumab, fingolimod, siponimod, cladribine, and ozanimod.4
A retrospective analysis of outcomes in newly diagnosed adult patients (N=1661) with ≥1 DMT claims of interferon, glatiramer acetate, or dimethyl fumarate from January 2016-March 2018 who were identified using a large US administrative claims database.5,6

Meet a few of the more than 30,000 patients prescribed KESIMPTA® (ofatumumab) as a first-line treatment, or after experience with other DMTs
Photo of Kristen, a patient.

"I started experiencing relapses on my previous treatment, and my doctor wanted me to try KESIMPTA."

Kristin: mom, real estate agent, RMS patient; initiated KESIMPTA in 2020

Kristin was ready for a different choice to manage her disease activity.

Despite being treated with a DMT, Kristin continued to be affected by relapsing MS.

Clinical factors:

  • Experienced recent relapse despite being on an oral first-line treatment

  • Evidence of lesion activity in recent MRI

Non-clinical factors:

  • Continued relapses despite treatment

  • Wants to find a treatment that works for her

  • Wants to reduce relapses in her life

Photo of Rachel, a patient.

"My doctor had found 2 new lesions. Now I take KESIMPTA to help me manage my relapsing MS."

Rachel: partner, stepmom, medical dosimetrist, RMS patient; initiated KESIMPTA in 2020

Rachel loves to travel. She doesn't love dealing with relapsing MS.

After trying 2 DMTs, Rachel was looking for more control over disease activity.

Clinical factors:

  • Previously on Aubagio®

  • 2 new lesions on recent MRI

  • 2 separate neurologists recommended KESIMPTA

Non-clinical factors:

  • Worried about potential side effects

  • Wants less frequent dosing

Photo of Walt, a patient.

"I chose KESIMPTA over infusions for my first RMS treatment. I can administer it myself at home."

Walt: husband, dad, aeronautical engineer, RMS patient; initiated KESIMPTA in 2021

Being diagnosed with relapsing MS was overwhelming.

Walt wanted a treatment that could help manage his relapsing MS activity.

Clinical factors:

  • An MRI for severe headache led to recent relapsing MS diagnosis

  • No previous DMT

Non-clinical factors:

  • Dislikes needles, refused infusions

  • Wants to treat at home

  • Feels at ease with Sensoready® Pen, despite initial concern about injections

Kristin, Rachel, and Walt are actual patients taking KESIMPTA who were compensated for their time. Individual results may vary.

Effect of high efficacy therapy on RMS when started earlier|| vs later in a retrospective, observational analysis8,9 
 

Cumulative risk of confirmed disability progression, measured from disease onset8

_

Adapted from He A, et al. Lancet Neurol. 2020.

In a 2020 retrospective international observational study, high efficacy therapy commenced within 2 years of disease onset was associated with less disability after 6-10 years of treatment, than when commenced later in the disease course. The group that received early high efficacy therapy started with more active RMS (based on EDSS score [2.54 vs 1.83]).8

High efficacy therapies included in the analysis were rituximab, ocrelizumab, alemtuzumab, and natalizumab. Other treatments included interferon, glatiramer acetate, and orals (fingolimod, teriflunomide, dimethyl fumarate, cladribine).8

No conclusions of statistical or clinical significance can be drawn. Consider retrospective observational study limitations when interpreting data. Further studies are needed to confirm findings.

A DMT is labeled as higher efficacy when the data show a more favorable treatment impact on at least relapses and disability progression. Some experts also prefer to evaluate MRI scans in considering relative efficacy.10

B-cell depletion is a key target for reducing RMS activity8-11

More and more physicians are choosing to start patients earlier with B-cell therapy, doubling prescription rates since 2016

Annual new prescription share of B-cell therapies12-14¶

This chart shows the annual NBRx share of B-cell therapy.

B-cell therapies account for 60% OF ALL NEW-TO-BRAND PRESCRIPTIONS from health care providers14¶

Experience with KESIMPTA keeps growing

Experience with KESIMPTA keeps growing

§Based on Novartis contracted specialty pharmacy and copay claims from launch through September 30, 2023.7       
||Within 2 years of disease onset.      
Based on annual new prescriptions share data from 2018 through August 2023. B-cell therapies include KESIMPTA® (ofatumumab), Ocrevus® (ocrelizumab), and Briumvi® (ublituximab-xiiy). KESIMPTA was approved in August 2020.12-14       
#Based on patient Start Forms completed through September 15, 2023 as reported by Novartis patient specialty services and NBRx reported by data contracted specialty pharmacies.14      
**Based on Symphony Health Physician prescribing data and IQVIA Drug Distribution Data through March 2023, and IQVIA OneKey physician affiliation with practices who have prescribed at least 20 KESIMPTA prescriptions in the last 12 months.16       
††Based on Symphony Health Anonymized Patient Level Data adjusted by IQVIA National Prescription Audit and National Sales Perspectives and Novartis contracted specialty pharmacy and copay claims data for January and February 2023.16      
‡‡Treatment naive: 35%, first DMT: 29%.16

See the most frequently asked questions about KESIMPTA

CI, confidence interval; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; HCP, health care professional; MOA, mechanism of action; MRI, magnetic resonance imaging; MS, multiple sclerosis; RMS, relapsing multiple sclerosis.

IMPORTANT SAFETY INFORMATION

Contraindication: KESIMPTA is contraindicated in patients with active hepatitis B virus infection.

WARNINGS AND PRECAUTIONS

Infections: An increased risk of infections has been observed with other anti-CD20 B-cell depleting therapies. KESIMPTA has the potential for an increased risk of infections including serious bacterial, fungal, and new or reactivated viral infections; some have been fatal in patients treated with other anti-CD20 antibodies...

INDICATION

KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
CoverMyMeds is a registered trademark of CoverMyMeds, LLC.
References: 1. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9:(suppl1)S5-S48. 2. Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e636. doi:10.1212/NXI.0000000000000636 3. MS in America: relapse frequency and duration. Accessed November 3, 2023. https://multiplesclerosis.net/living-with-ms/multiple-sclerosis-relapses 4. Data on file. US Symphony ALPD Q4 2020 Data. Novartis Pharmaceuticals Corp; East Hanover, NJ. December 2020. 5. Conway D, Hersh C, Wang M, Yang F, Deshpande C. Treatment failure in patients with multiple sclerosis initiating frequently used first line therapies. PO02. Poster presented at: 8th Joint ACTRIMS-ECTRIMS Meeting MS; September 11-13, 2020; Virtual. 6. Data on file. HEOR US unmet needs. Novartis Pharmaceuticals Corp; East Hanover, NJ. July 2020. 7. Data on file. KESIMPTA prescriptions. Novartis Pharmaceuticals Corp; East Hanover, NJ. October 2023. 8. He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307-316. 9. Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-efficacy therapies for treatment-naïve individuals with relapsing-remitting multiple sclerosis. CNS Drugs. 2022;36(12):1285-1299. 10. Simpson A, Mowry EM, Newsome AD. Early aggressive treatment approaches for multiple sclerosis. Curr Treat Options Neurol. 2021;23(7):19. doi:10.1007/s11940-021-00677-1 11. Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76(5):536-541. 12. Data on file. MS integrated NBRx market share 2021. Novartis Pharmaceuticals Corp; East Hanover, NJ. March 2022. 13. Data on file. NBRx adjusted share. Novartis Pharmaceuticals Corp; East Hanover, NJ. October 2022. 14. Data on file. B-cell NBRx market share. Novartis Pharmaceuticals Corp; East Hanover, NJ. August 2023. 15. Data on File. Kesimpta Start Forms Data. Novartis Pharmaceuticals Corp; East Hanover, NJ. 2023. 16. Data on file. Experience NBRx. Novartis Pharmaceuticals Corp; East Hanover, NJ. 2023.